Trial Profile
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2024
Price :
$35
*
At a glance
- Drugs Obicetrapib (Primary)
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Acronyms BROADWAY
- Sponsors NewAmsterdam Pharma
- 08 Jan 2024 According to a NewAmsterdam Pharma media release, company began enrolling patients in this trial in January 2022 and completed enrollment in July 2023.
- 04 Jan 2024 According to a NewAmsterdam Pharma media release, the company expects to report topline data in the fourth quarter of 2024.
- 31 Aug 2023 Planned End Date changed from 1 May 2024 to 1 Sep 2024.